Abstract B008: Pan-RAS-GTP inhibition disrupts the KRAS-SHH axis to reprogram cancer-associated fibroblast subtypes and reduce stiffness in pancreatic cancer
It is demonstrated that pharmacological RAS inhibition fundamentally reprograms the pancreatic stroma by dismantling the KRAS-SHH-myCAF axis, remodeling the ECM, and softening the biomechanical barrier that characterizes PDAC.